| 臺大學術典藏 |
2021-09-04T06:12:38Z |
Hepatitis B viral load as a prognostic factor for patients with unresectable hepatocellular carcinoma
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:38Z |
Reply [2]
|
Lin C.-L.; Liu C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:34Z |
Hepatitis B viral genotype in Taiwanese patients with acute hepatitis B
|
Huang Y.-W.; Lin C.-L.; Chen P.-J.; Lai M.-Y.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:12:32Z |
Hepatitis B viral factors and clinical outcomes of chronic hepatitis B
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:24Z |
HBV genotypes and chronicification of acute hepatitis B: More questions than answers
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:21Z |
Optimal management of hepatocellular carcinoma: Challenges and opportunities
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:20Z |
Clinical implications of hepatitis B virus variants
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:13Z |
The clinical implications of hepatitis B virus genotype: Recent advances
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:11Z |
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy
|
Tseng T.-C.; Yu M.-L.; Liu C.-J.; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; Liu C.-H.; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:06Z |
Recent advances in the treatment of chronic hepatitis B
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:01Z |
Host genetic variants and hepatitis b virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission
|
Lin C.-L.; Tseng T.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Lai M.-Y.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:00Z |
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:00Z |
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:54Z |
Risk stratification for hepatitis B virus related hepatocellular carcinoma
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:54Z |
Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir
|
Wang C.-C.; Tseng K.-C.; Peng C.-Y.; Hsieh T.-Y.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Hsu C.-S.; Lin H.H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:51Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; JIA-HORNG KAO; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T06:11:47Z |
Hepatitis B virus genotypes: Clinical relevance and therapeutic implications
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:47Z |
Hepatitis B viral factors and treatment responses in chronic hepatitis B
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:35Z |
What can we learn from hepatitis B virus clinical cohorts?
|
Lin C.-L.; Tseng T.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:33Z |
Hepatitis B virus genotypes and variants
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:32Z |
Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B
|
Lin C.-L.; Liu C.-H.; Wang C.-C.; Liang C.-C.; Su T.-H.; Liu C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:31Z |
Perspectives and control of hepatitis B virus infection in Taiwan
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:31Z |
Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients
|
Wang C.-C.; Liu C.-H.; Lin C.-L.; Wang P.-C.; Tseng T.-C.; Lin H.H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:28Z |
HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
|
Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:27Z |
Comparison of abbott realtime HCV genotype II with versant line probe assay 2.0 for hepatitis C virus genotyping
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:25Z |
Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial
|
Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:22Z |
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na?ve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial
|
Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:21Z |
Hepatitis B virus: New therapeutic perspectives
|
Lin C.-L.; Yang H.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:21Z |
Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B?
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:19Z |
New perspectives of biomarkers for the management of chronic hepatitis B
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:18Z |
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan
|
Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; Su T.-H.; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:15Z |
Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues
|
Tseng K.-C.; Tseng C.-W.; Hsieh T.-Y.; Peng C.-Y.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:14Z |
Review article: novel therapies for hepatitis B virus cure – advances and perspectives
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:08Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; JIA-HORNG KAO; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2021-09-04T06:11:07Z |
Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:02Z |
Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:17:09Z |
Prevention of mother-to-child transmission: the key of hepatitis B virus elimination
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:17:05Z |
Review article: the prevention of hepatitis B-related hepatocellular carcinoma
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:59Z |
Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan
|
Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:51Z |
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
|
Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:46Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:36Z |
Hepatitis B: Immunization and Impact on Natural History and Cancer Incidence
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:29Z |
Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy
|
Lin C.-L.; Tseng K.-C.; Chen K.-Y.; Liao L.-Y.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:21Z |
Response to letter to the editor “Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy”
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:16Z |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; Liu C.-J.; Dai C.-Y.; JIA-HORNG KAO; Chuang W.-L.; Lin H.-C.; Yu M.-L. |
| 臺大學術典藏 |
2021-09-02T00:09:17Z |
Single allele Lmbrd1 knockout results in cardiac hypertrophy
|
Tseng L.T.-L;Lin C.-L;Pan K.-H;Tzen K.-Y;Su M.-J;Tsai C.-T;Li Y.-H;Li P.-C;Chiang F.-T;Chang S.C;Chang M.-F.; Tseng L.T.-L; PAI-CHI LI et al. |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2021-08-05T02:38:18Z |
Facile Fabrication of Microwrinkled Poly(3,4-Ethylenedioxythiophene) Films that Promote Neural Differentiation under Electrical Stimulation
|
Hsiao Y.-S;Lin C.-L;Liao I.-H;Chen F.-J;Liu C.-T;Tseng H.-S;Yu J.; Hsiao Y.-S; Lin C.-L; Liao I.-H; Chen F.-J; Liu C.-T; Tseng H.-S; Yu J.; JIASHING YU |
| 臺大學術典藏 |
2021-08-05T02:37:15Z |
Design and evaluation of a 3D multi-manifold micromixer realized by a double-Archimedes-screw for rapid mixing within a short distance
|
Shin C.-S;Baldeck P.L;Nie Y.-M;Lee Y.-H;Lin Z.-D;Chiang C.-C;Lin C.-L.; Shin C.-S; Baldeck P.L; Nie Y.-M; Lee Y.-H; Lin Z.-D; Chiang C.-C; Lin C.-L.; CHOW-SHING SHIN |
| 臺大學術典藏 |
2021-08-03T07:10:53Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
YU-YUN SHAO; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
